Immunotech Relocates to New Research & Development Laboratory Facility
01 3월 2013 - 11:15PM
Marketwired
Immunotech Laboratories, Inc. (PINKSHEETS:
IMMB) today announced the company has relocated to a new Research
& Development Lab facility in Monrovia, California.
The new facility incorporates more laboratory use of the actual
facility than the combined Administrative space at the previous
Pasadena location. The new location also is geographically more
conveniently located for the Immunotech team.
In light of the recent announcements stating the HIV-AIDS and
Hepatitis C clinical trials using the company's patented "ITV-1"
patented technology treatment by the Immunotech BG sister company,
more clinical research and results testing is necessary. The new
facility accommodates the additional lab space.
Utilizing a combination of the clinical tests and results being
conducted in Bulgaria alongside the results analysis here in the
USA at the new facility, Immunotech plans to submit all the results
from the Bulgarian clinical trials for US Food & Drug
Administration "FDA" approval on a pre IND meeting. Immunotech
Laboratories plans to start working with IND Directions, LLC
(http://inddirections.com)
Immunotech's ultimate goal is to provide a worldwide FDA
approved treatment for combating the HIV-AIDS virus with the intent
of terminating the virus and restoring the immune system. The goal
of this treatment is to achieve reduction of resistance of existing
therapies on the market.
The clinical trials in Bulgaria (Referred to as EU) are
scheduled to begin in May 2013 and end in October 2013, which will
give Immunotech, the rights to receive approval for applications of
the "IPF" Treatment. In this respect, Immunotech Laboratories BG
has had a series of conversations with Mr. Vladimir Stoichev, the
Deputy General Director from Sopharma Bulgaria, and the parties
have had talks for the possible signing of a contract between
Immunotech Laboratories BG and Sopharma for joint production of
IPF-ITV. Sopharma is a leading pharmaceutical
company in the European Union.
RELEVANT ARTICLES & LINKS FOR AIDS-HIV
MEDICINES
http://news.yahoo.com/gsk-wins-priority-status-hiv-drug-u-161639474--finance.html
About Immunotech Laboratories Immunotech
Laboratories is a drug development company committed to the
commercialization of its proprietary proteins for the treatment of
debilitating infectious diseases such as HIV, Cancer, Hepatitis and
Aids. www.immunotechlab.com
Safe Harbor Statement: This news release
contains forward-looking statements that involve risks and
uncertainties associated with financial projections, budgets,
milestone timelines, clinical development, regulatory approvals,
and other risks described by Immunotech Laboratories, Inc. from
time to time in its periodic reports filed with the SEC. IPF is not
approved by the US Food and Drug Administration or by any
comparable regulatory agencies elsewhere in the world. While
Immunotech Laboratories believes that the forward-looking
statements and underlying assumptions contained therein are
reasonable, any of the assumptions could be inaccurate, including,
but not limited to, the ability of Immunotech Laboratories to
establish the efficacy of IPF in the treatment of any disease or
health condition, the development of studies and strategies leading
to commercialization of IPF in the United States, the obtaining of
funding required to carry out the development plan, the completion
of studies and tests on time or at all, and the successful outcome
of such studies or tests. Therefore, there can be no assurance that
the forward-looking statements included in this release will prove
to be accurate. In light of the significant uncertainties inherent
in the forward-looking statements included herein, Immunotech
Laboratories or any other person that the objectives and plans of
Immunotech Laboratories will be achieved should not regard the
forward-looking statements as a representation.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Company Contact: Immunotech Laboratories, Inc. Email Contact
Investor Relations: The Nabors Group 713-875-9200 E-mail: Email
Contact www.facebook.com/Naborsgroup
Immunotech Laborator (CE) (USOTC:IMMB)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Immunotech Laborator (CE) (USOTC:IMMB)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024